Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: A meta-analysis

Cardiovascular Revascularization Medicine

Volumn 11, Issue 4, 2010, Pages 227-231

  Nishio, Kazuaki ^a   Kobayashi, Youichi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary stent; Pioglitazone; Restenosis; Rosiglitazone; Target vessel revascularization

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ANGINA PECTORIS; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG SAFETY; EDEMA; HEADACHE; HUMAN; LIVER DYSFUNCTION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; STENT THROMBOSIS; SYSTEMATIC REVIEW;

AGED; ANGIOPLASTY, BALLOON; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METALS; MIDDLE AGED; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STENTS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957735779     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2009.06.001     Document Type: Article

References (29)

1. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998, 32:1866-1873.
2. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig J Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999, 34:1498-1506.
3. Mudra H, di Marco C, de Jaegere P, Figulla HR, Macaya C, Zahn R, Wennerblom B, Rutsch W, Voudris V, Regar E, Henneke KH, Schachinger V, Zeiher A A randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation 2001, 104:1343-1349.
4. Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, Lopez-Minguez JR, Moreu J, Calvo I, Ramirez JA, Alonso M, Vazquez N, Lezaun R, Rodriguez C Direct coronary stenting versus stenting with balloon predilation: the DISCO trial: Direct Stenting of COronary Arteries. Eur Heart J 2002, 23:633-640.
5. Gilbert J, Raboud J, Zinman B Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004, 27:990-994.
6. Scheen AJ, Warzée F Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care 2004, 27:1840-1841.
7. Riche DM, Valderrama R, Henyan NN Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention. Diabetes Care 2007, 30:384-388.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
9. Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
10. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with Type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.
11. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792-2798.
12. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with Type 2 diabetes. Diabetes Care 2006, 29:101-106.
13. Katayama T, Ueba H, Tsuboi K, Kubo N, Yasu T, Kuroki M, Saito M, Momomura S, Kawakami M Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 2007, 153:762.e1-762.e7.
14. Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, Uretsky BF Effect of rosiglitazone on restenosis after coronary stenting in patients with Type 2 diabetes. Am Heart J 2004, 147:e23.
15. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
16. Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 2005, 54:590-597.
17. Miyazaki Y, Mahankali A, Matsuda M Improved glycemic control and enhanced insulin sensitivity in Type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001, 24:710-719.
18. Goetze S, Xi XP, Kawano H PPAR gamma-ligands inhibits migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999, 33:798-806.
19. Igarashi M, Hirata A, Yamaguchi H Characterization of an inhibitory effect of pioglitazone in balloon-injured vascular smooth muscle cell growth. Metabolism 2001, 50:955-962.
20. Pakala R, Dilcher C, Baffour R, Hellinga D, Seabron R, Joner M, Kolodgie F, Virmani R, Waksman R Peroxisome proliferator-activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. J Cardiovasc Pharmacol 2006, 48(6):299-305.
21. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK, Virmani R Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 2007, 27(1):182-189.
22. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002, 40:687-693.
23. Singh S, Loke YK, Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
24. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
25. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, Study Investigators A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
26. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH, GLAI Study Investigators Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 2007, 30:2458-2464.
27. Cao Z, Zhou Y, Zhao Y, Liu Y, Guo Y, Cheng W Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome. Chin Med J 2006, 119:1171-1175.
28. Nishio K, Fukui T, Tsunoda F, Kawamura K, Itoh S, Konno N, Ozawa K, Katagiri T Insulin resistance as an independent risk factor for restenosis after coronary stenting. Int J Cardiol 2005, 103:128-134.
29. Nissen SE, Nicholls SJ, Wolski K, et al. Periscope Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the Periscope randomized controlled trial. JAMA 2008, 299:1561-1573.